Key terms
About INKT
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INKT news
Apr 08
12:02pm ET
MiNK announces presentation of MiNK-215 data at AACR meeting
Mar 24
9:48pm ET
Buy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial Moves
Mar 21
11:25am ET
Promising Clinical Progress and Market Potential for MiNK Therapeutics’ agenT-797 in Gastric Cancer Study
Mar 21
7:02am ET
MiNK Therapeutics reports Q4 EPS (16c), consensus (15c)
Mar 06
8:41am ET
MiNK Therapeutics announces preclinical data from MiNK-215
Feb 14
8:11am ET
MiNK Therapeutics announces first patient dosed in Phase 2 study for agenT-797
Feb 09
1:02am ET
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BridgeBio Pharma (BBIO)
Feb 06
8:06am ET
MiNK announces publication of results from Phase 1/2 study of agenT-797
Jan 30
8:18am ET
MiNK Therapeutics announces publication of case report on agenT-797
No recent press releases are available for INKT
INKT Financials
Key terms
Ad Feedback
INKT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INKT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
